And three! The fate of this third vaccine developed to fight Covid-19 is now known. On Tuesday February 2, the French National Authority for Health announced that the AstraZeneca vaccine was not recommended for people over 65 years of age with regard to the lack of available data regarding efficiency in this age group. “There is a lack of data for patients over 65, these data will arrive in the coming weeks, in the meantime, we recommend its use in those under 65,” said the president of HAS, Dominique Le Guludec, during an online press point. Before specifying: “This opinion will be reviewed in the light of additional clinical data that we are awaiting shortly”. Regarding the interval between the two doses, the second is to be done between 9 and 12 weeks after the first injection.
At the end of last week, the European Medicines Agency (EMA) had authorized this product for all adults over 18 years old. Reservations identical to France have been reported by health authorities in several European countries such as Germany, Austria, Italy, Poland and Sweden.
This viral vector vaccine was developed by the British pharmaceutical group in partnership with the University of Oxford. “This vaccine has a completely satisfactory performance, between 62 and 70% efficiency according to the studies “, underlined the HAS during the press conference.
Another change, the High Authority of Health has also announced that the AstraZeneca vaccine can be administered by pharmacists and midwives in addition to nurses and doctors. Indeed, this antidote can be stored long term in conventional fridges at temperatures between 4 and 8 degrees unlike the two other vaccines already available, those from Pfizer / BioNTech and Moderna.
The HAS recommends that it be administered as a priority to health and medico-social professionals and to people aged 50 to 64, starting with those who have comordities. These populations correspond to the populations prioritized in phase 3 of the vaccination strategy which also includes 18-49 year olds with co-morbidities and essential operators and professionals in sectors essential to the functioning of the country.
Among the causes of comorbidities:
- obesity (BMI> 30), especially in the youngest;
- COPD and respiratory failure;
- complicated arterial hypertension;
- heart failure;
- diabetes (type 1 and type 2);
- chronic renal failure;
- cancers and malignant haematological diseases that are active and less than 3 years old;
- having a solid organ or hematopoietic stem cell transplant.
This opinion must now be ratified by the government. The Haute Autorité de Santé hopes to receive around 10 million doses within three months. Thus, five million additional people could be vaccinated against Covid-19.
To find out more about the coronavirus, the editorial staff invites you to discover its more complete and regularly updated articles:
- an article on Covid-19 disease and the evolution of the epidemic
- an article on the different screening tests
- an article on vaccines under development.